Quick Facts: Antela

• Approved Use: Management of specific forms of adult gastroesophageal junction adenocarcinoma.
• Therapeutic Role: Utilized in combination with other agents for perioperative treatment.

---

Antela is a prescription medication used to address certain forms of cancer in adult patients. Its approved therapeutic domain is the perioperative treatment of resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. The medication is administered alongside a standard chemotherapy regimen, both before and after surgical intervention, as part of a comprehensive care plan.

The goal of this treatment approach is to help manage the progression of the disease. Antela functions as an approved therapeutic option within the context of a monitored oncology program.

Who Can and Cannot Use Antela? (Desogestrel and Ethinyl Estradiol)

The eligibility criteria for Antela, a combined oral contraceptive (COC), are determined by official regulatory documents that define specific contraindications and population restrictions.

Absolute Contraindications

Antela must not be used by individuals with a history of or current diagnosis of the following:

• Thromboembolic Disorders: History of deep vein thrombosis (DVT) or pulmonary embolism (PE), cerebral vascular, or coronary artery disease.
• Hormone-Sensitive Malignancies: Known or suspected carcinoma of the breast or other estrogen-dependent tumors.
• Liver Disease: Hepatic tumors (benign or malignant), active liver disease, or severe hepatic impairment.
• Age and Lifestyle: Women over 35 years of age who smoke.
• Neurological: History of migraine with focal neurological symptoms.
• Pregnancy Status: Known or suspected pregnancy.

Population Restrictions

Population Group	Eligibility Status
Pediatric Use	Contraindicated before the start of menstruation (menarche).
Geriatric Use	Not indicated for use in elderly (postmenopausal) women.
Lactation	Not recommended due to potential for harmful infant effects and reduction in milk quality.
Surgical Procedures	Must be discontinued at least four weeks before and for two weeks after major surgery or prolonged immobilization.
Organ Impairment	Use is not formally established in patients with severe hepatic or renal insufficiency.

The official regulatory profile for Antela is primarily defined by restrictions based on pharmacodynamic interference and specific procedural requirements for administration.

Documented Drug-Drug Interaction Patterns

Antela is not recommended for use with systemic corticosteroids or other systemic immunosuppressants if they are administered prior to initiating therapy, as these agents may interfere with the drug's intended pharmacodynamic activity. This restriction applies to all but non-immunosuppressive doses of systemic corticosteroids.

Conversely, regulatory studies document that Antela exhibits metabolic neutrality when co-administered with several common chemotherapy agents, including cisplatin, carboplatin, and etoposide. These co-administered drugs do not result in a clinically meaningful change in the plasma concentration or clearance of Antela.

Administration and Procedural Constraints

Antela must not be co-administered through the same intravenous infusion line with any other therapeutic product; separate infusion bags and equipment are strictly required for each drug. In specific combination regimens, the administration sequence is defined: the co-administered immune checkpoint inhibitor, Tremelimumab, is infused first, followed by Antela. Additionally, a specific official caution exists regarding the risk of serious complications when Antela is used in relation to Allogeneic Hematopoietic Stem Cell Transplant (HSCT).

Selective Modulation of Inhibitory Receptors

Antela functions as a Positive Allosteric Modulator (PAM) that targets specific GABA A receptor subunits in the central nervous system (CNS), enhancing the functional response of the GABA neurotransmitter at the receptor. This molecular mechanism increases the frequency of chloride ion channel opening, thereby increasing the influx of negative ions into the postsynaptic neuron.

Alteration of Central Nervous System Excitability

The enhanced GABA A receptor function causes hyperpolarization of the target neurons, which results in a decreased neuronal firing rate. This targeted effect alters signaling dynamics within the limbic system and related pathways that influence emotional and arousal processes, consequently altering the output of circuits characterized by increased basal activity.

Modulation of Central Arousal and Motor Control Pathways

The systemic outcome of this potentiation is a change in the activity of major physiological systems governing arousal and muscle tone. These effects correspond to a reduction in the excitability of circuits regulating arousal and motor output, resulting in a measurable decrease in overall neural activity and muscular activation.

Antela is administered solely as an intravenous infusion under specialist supervision, following a highly structured, phased treatment protocol. The treatment regimen involves two distinct methods for dose determination based on patient weight: those weighing 30 kg or more receive a fixed dose of 1,500 mg per infusion, while patients weighing less receive a weight-based dose of 20 mg/kg.

The overall treatment is structured cyclically, with administrations typically occurring every four weeks (Q4W). The course is defined by neoadjuvant (pre-surgery) and adjuvant (post-surgery) periods. Antela is administered alongside FLOT chemotherapy in the initial cycles. On days when both Antela and chemotherapy are scheduled, Antela is administered prior to the chemotherapy agents to maintain the treatment sequence.

Prior to delivery, the medication concentrate must be diluted to achieve the required concentration range. The resulting solution is then delivered over a period of 60 minutes and requires the use of a sterile, low-protein binding 0.2 or 0.22 micron in-line filter during the infusion process. Treatment may continue in the adjuvant setting for a period of up to 12 cycles after the surgical intervention.

Research Evidence: Overview of Studies for Antela

Evidence for use in Preventing Unintended Pregnancy

Research examining Antela's specific hormone combination (Desogestrel and Ethinyl Estradiol) for contraception has been conducted over several decades, utilizing large-scale clinical trials and long-term observational cohort studies. The core outcome examined is the Pearl Index, a standardized measure of unintended pregnancy frequency during use. Findings describe patterns observed in these studies, reporting measurements related to the prevention of conception under both perfect and typical use conditions. Research does not determine whether an individual will respond similarly to the group patterns reported, and data remains limited for certain subgroups with complex medical histories.

Evidence for use in Resectable Gastric and GEJ Adenocarcinoma

Antela was evaluated in a pivotal Randomized, Double-Blind, Placebo-Controlled Phase III Trial as part of a combination regimen for adults diagnosed with specific forms of resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma. The primary outcome researchers examined was Event-Free Survival (EFS), which monitors the time until the disease recurs, progresses, or until death. Secondary research explored Overall Survival (OS) and Pathological Complete Response (pCR).

Areas of Research Uncertainty and Study Gaps

The evidence base for Antela contains areas where research is still developing or where information is limited. This includes a need for continued follow-up to establish final long-term outcomes for the cancer indication, limited data concerning patients with specific health risks in contraceptive studies, and research findings that do not isolate the individual contribution of Antela outside of its mandatory combination regimens.

Key Studies & References Birth Control Pills - MedlinePlus

Common questions about Antela (FAQ)

Q: What is Antela used for besides its main listed purpose?

A: Regulatory documents define two primary roles for Antela. The first is the prevention of unintended pregnancy using the oral tablet form. The second, using the intravenous infusion, is for treating specific forms of Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma as part of a combination regimen.

Q: Does Antela contain steroids?

A: According to official product information, Antela contains the two synthetic hormones, Desogestrel (a progestogen) and Ethinyl Estradiol (an estrogen). These synthetic hormones are described as being in the same chemical family as steroids, distinct from corticosteroids sometimes used for inflammation.

Q: Is Antela a new drug or has it been around for a long time?

A: Studies related to the hormone combination used in Antela (Desogestrel and Ethinyl Estradiol) have been conducted over several decades. However, the evidence supporting its use in specific cancer combination regimens is more recent, relying on pivotal Phase III trials. Therefore, the drug’s components have a long research history, while its use in certain indications is newer.

Q: Is Antela known to affect blood sugar levels?

A: Official safety documents list potential side effects that affect various body systems. Official safety documentation reports Type 1 diabetes mellitus as a potential severe immune-mediated adverse reaction that can affect the endocrine system.

Q: Can Antela be used by people with kidney problems?

A: Official documentation states that the medicine's use is not formally established in patients who have severe renal (kidney) insufficiency. Use is based on official contraindications and population restrictions.

Q: Is Antela known to cause problems with sleeping?

A: The medication’s mechanism of action is described as functioning in the central nervous system (CNS). Official information states this action causes a reduction in the excitability of neural circuits that regulate arousal and motor output.

Q: Are there different strengths or forms of Antela available?

A: Yes, Antela is supplied in different forms depending on the indication. It is available as a monophasic, coated oral tablet for its contraceptive use. For its cancer indication, it is supplied as an intravenous infusion concentrate, which requires dilution and is administered following one of two distinct dose calculation methods.

Q: How does Antela affect the immune system?

A: The official safety profile organizes potential side effects by the affected body system. For the cancer indication, regulatory documents list the risk of severe immune-mediated adverse reactions. These reactions involve the body’s immune system mistakenly targeting healthy tissue and can affect multiple organs, including the lungs, colon, and liver.

Q: What information is available about the long-term use of Antela?

A: Regarding the cancer indication, official research evidence states there is a need for continued patient follow-up. This ongoing monitoring is necessary to establish and finalize the long-term outcomes, such as Event-Free Survival and Overall Survival, of the treatment.

How to Store and Dispose of Antela?

This section details the officially documented storage and disposal requirements for Antela (Desogestrel and Ethinyl Estradiol tablets).

Official Storage Requirements

Storage Condition	Requirement
Temperature	Store at room temperature.
Environmental Protection	Protect from excess heat and moisture; do not store in the bathroom.
Packaging	Keep in the original container and ensure it is tightly closed.
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Antela must be disposed of using an approved method, such as participating in an official drug take-back program. If a take-back program is unavailable, the medication may be placed in household trash after being mixed with an undesirable substance to prevent access by children or pets. Disposal must comply with local regulatory requirements for pharmaceutical waste.